Scrip Asks…What Does 2022 Hold For Biopharma? Part 4: Therapeutic Area Advances
High Hopes In COVID-19, Cancer, CNS, Immunology And Rare Disease
Evolving challenges will keep the COVID-19 pipeline active, while oncology, immunology and CNS are areas also expected to see much progress in 2022. Industry executives look forward to the year in therapeutic R&D.
You may also be interested in...
Zydus has established proof of concept for ZYIL1, a NLRP3 inflammasome inhibitor to treat cryopyrin-associated periodic syndromes, via Phase II trials in Australia. Will the oral drug have an upper hand over injectables like Novartis’ Ilaris?
In this week's podcast edition of Five Must-Know Things: the pharma industry reacts to the Ukraine situation; a guide to targeted protein degradation; Janssen/Legend’s US pricing and launch plans for Carvykti; Ipsen seeks multiple licensing deals; and the fourth in the Scrip Asks series looks at prospects for therapeutic advances.
The Merck & Co vaccine for human papillomavirus Gardasil, along with Johnson & Johnson’s Darzalex for multiple myeloma, entered the ranks of the top 10 best-selling drugs globally in the second quarter. There was no product for COVID-19 in the line-up for the first time since 2020.